Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

How Cullgen is expanding the repertoire of E3 ligases used in protein degradation

Inhua Muijrers-Chen, Associate Editor
September 6, 2019 6:27 PM UTC

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases.

With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen Inc. is developing small molecules that link disease-causing proteins to previously untapped E3 ubiquitin ligases in the cullin ring family, which recruit ubiquitin to induce proteasome-mediated degradation. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

A-Alpha Bio Inc.

Arvinas Inc.

C4 Therapeutics Inc.

Cedilla Therapeutics Inc.

Cullgen Inc.

Kymera Therapeutics Inc.

Nurix Therapeutics Inc.